e-learning
resources
Glasgow 2004
Sunday 05.09.2004
Treatment of lung cancer and lung metastases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Combination chemotherapy with gemcitabine using isolated lung perfusion for the treatment of lung metastases
B. P. Van Putte, J. M. H. Hendriks, S. Romijn, B. Pauwels, J. B. Vermorken, P. E. Y. Van Schil (Edegem, Belgium)
Source:
Annual Congress 2004 - Treatment of lung cancer and lung metastases
Session:
Treatment of lung cancer and lung metastases
Session type:
Poster Discussion
Number:
388
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. P. Van Putte, J. M. H. Hendriks, S. Romijn, B. Pauwels, J. B. Vermorken, P. E. Y. Van Schil (Edegem, Belgium). Combination chemotherapy with gemcitabine using isolated lung perfusion for the treatment of lung metastases. Eur Respir J 2004; 24: Suppl. 48, 388
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Toxicity in isolated lung perfusion with melphalan for resectable lung metastases
Source: Annual Congress 2006 - Contemporary issues in thoracic surgical oncology
Year: 2006
Initial combined intratumoral chemotherapy with cisplatin and irradiation for inoperable non-small cell obstructive lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 492s
Year: 2004
Temozolomide in the treatment of brain metastases in lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 65s
Year: 2003
Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial
Source: Eur Respir J 2004; 24: Suppl. 48, 42s
Year: 2004
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer
Source: Eur Respir J 2006; 27: 1183-1189
Year: 2006
Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection?
Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications
Year: 2019
Treatment of limited disease-small cell lung cancer
Source: Eur Respir Mon; 2009: 44: 299–309
Year: 2009
Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 433s
Year: 2007
Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
Resistance to chemotherapy in lung cancer
Source: International Congress 2015 – Resistance to therapy in lung cancer
Year: 2015
Adjuvant therapy in NSCLC
Source: Annual Congress 2007 - Clinical year in review
Year: 2007
Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Second-line weekly docetaxel in advanced non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Clinical characteristic of lung cancer patients with interstitial pneumonia treated with chemotherapy or radiotherapy
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept